Tobacco dependence is a chronic relapsing disease that needs continuous treatment. In combination with behavioural support, pharmacotherapy is a proven key component for supporting smoking cessation. Effective drugs are available and recommended: nicotine replacement therapy (NRT), bupropion and varenicline. Much research into new pharmacological approaches is ongoing, combining 'old' and 'new' drugs and personalizing a pharmacological treatment for a single smoker/patient; other new medications and vaccines are in development. Overall, pharmacotherapy seems to have efficacy and cost-effectiveness in real life, thus physicians should become familiar with these medicines. Further efforts should be aimed at optimizing treatment management and increasing smoking cessation rates in the general population.
American Psychiatric Association (1994) edn, Diagnostic and Statistical Manual of Mental Disorders: DSM-IV ., 4th edition. 4thWashington, DCAmerican Psychiatric Press.
2.
Anthonisen, N.R., Connett, J.E., Kiley, J.P., Altose, M.D., Bailey, W.C., Buist, A.S. et al. (1994) Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study, JAMA272: 1497-1505.
3.
Aubin, H.J., Bobak, A., Britton, J.R., Oncken, C., Billing Jr, C.B., Gong, et al. (2008) Varenicline versus transdermal nicotine patch for smoking cessation: Results from a randomised, open-label trial, Thorax (Epub ahead of print) .
4.
Bertram, M.Y., Lim, S.S., Wallace, A.L. and Vos, T. (2007) Costs and benefits of smoking cessation aids: making a case for public reimbursement of nicotine replacement therapy in Australia , Tob Control16: 255-260.
5.
Biberman, R., Neumann, R., Katzir, I. and Gerber, Y. (2003) A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation, Addiction98: 1403-1407.
6.
Cahill, K., Stead, L.F. and Lancaster, T. (2007) Nicotine receptor partial agonists for smoking cessation, Cochrane Database Syst Rev CD006103.
7.
Cahill, K. and Ussher, M. (2007) Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation, Cochrane Database Syst Rev CD005353.
8.
Carrozzi, L., Pistelli, F., Fornai, E., Desideri, M., Viegi, G. and Giuntini, C. (2000) Smoking cessation clinic: an Italian experience , Monaldi Arch Chest Dis55: 502-505.
9.
Chatkin, J.M., Abreu, C.M., Blanco, D.C., Tonietto, R., Scaglia, N., Wagner, M.B. et al. (2006) No gender difference in effectiveness of smoking cessation treatment in a Brazilian real-life setting, Int J Tuberc Lung Dis10: 499-503.
10.
Cornuz, J., Gilbert, A., Pinget, C., McDonald, P., Slama, K., Salto, E. et al. (2006) Cost-effectiveness of pharmacotherapies for nicotine dependence in primary care settings: a multinational comparison , Tobacco Control15: 152-159.
11.
Cromwell, J., Bartosch, W.J., Fiore, M.C., Hasselblad, V. and Baker, T. (1997) Cost-effectiveness of the clinical practice recommendations in the AHCPR guidelines for smoking cessation. Agency for Health Care Policy and Research, JAMA278: 1759-1766.
12.
David, S.P., Brown, R.A., Papandonatos, G.D., Kahler, C.W., Lloyd-Richardson, E.E., Munafo, M.R. et al. (2007) Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation, Nicotine Tob Res9: 821-833.
13.
David, S., Lancaster, T., Stead, L.F. and Evins, A.E. (2006) Opioid antagonists for smoking cessation, Cochrane Database Syst Rev CD003086.
14.
D'Orlando, K.J. and Fox, B.S. (2004) Tolerability and pharmacokinetics of single and repeated doses of nicotine with the Straw, a novel nicotine replacement product , Nicotine Tob Res6: 63-70.
15.
Epstein, A.M. and King, A.C. (2004) Naltrexone attenuates acute cigarette smoking behavior , Pharmacol Biochem Behav77: 29-37.
16.
Farrell, M., Howes, S., Bebbington, P., Brugha, T., Jenkins, R., Lewis, G. et al. (2001) Nicotine, alcohol and drug dependence and psychiatric comorbidity. Results of a national household survey, Br J Psychiatry179: 432-437.
17.
Fiore, M.C., Jaén, C.R., Baker, T.B., Bailey, W.C., Benowitz, N.L., Curry, S.J. et al. (2008) Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MDUS Department of Health and Human Services, Public Health Service. May 2008.
18.
Food and Drug Administration (2006) The FDA approves new drug for smoking cessation, FDA Consum40: 29.
19.
Fowler, J.S., Volkow, N.D., Wang, G.J., Pappas, N., Logan, J., Shea, C. et al. (1996) Brain monoamine oxidase A inhibition in cigarette smokers, Proc Natl Acad Sci USA93: 14065-14069.
20.
Gadde, K.M. and Xiong, G.L. (2007) Bupropion for weight reduction, Expert Rev Neurother7: 17-24.
21.
Gelfand, E.V. and Cannon, C.P. (2006) Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors, J Am Coll Cardiol47: 1919-1926.
22.
George, T.P., Vessicchio, J.C., Termine, A., Jatlow, P.I., Kosten, T.R. and O'Malley, S.S. (2003) A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation, Biol Psychiatry53: 136-143.
23.
Gilpin, E.A., Messer, K. and Pierce, J.P. (2006) Population effectiveness of pharmaceutical aids for smoking cessation: what is associated with increased success?, Nicotine Tob Res8: 661-669.
24.
Godfrey, C., Parrot, S., Coleman, I. and Pound, E. (2005) The cost-effectiveness of the English smoking treatment services: evidence from practice, Addiction100: 70-83.
25.
Gonzales, D.H., Nides, M.A., Ferry, L.H., Kustra, R.P., Jamerson, B.D., Segall, N. et al. (2001) Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: a randomized placebo-controlled study, Clin Pharmacol Ther69: 438-444.
26.
Gonzales, D., Rennard, S.I., Nides, M., Oncken, C., Azoulay, S., Billing, C.B. et al. (2006) Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial, JAMA296: 47-55.
27.
Gourlay, S.G., Stead, L.F. and Benowitz, N.L. (2004) Clonidine for smoking cessation, Cochrane Database Syst Rev CD000058.
28.
Hatsukami, D.K., Rennard, S., Jorenby, D., Fiore, M., Koopmeiners, J., de Vos, A. et al. (2005) Safety and immunogenicity of a nicotine conjugate vaccine in current smokers, Clin Pharmacol Ther78: 456-467.
29.
Hatsukami, D.K., Stead, L.F. and Gupta, P.C. (2008) Tobacco addiction, Lancet371: 2027-2038.
30.
Henningfield, J.E., Fant, R.V., Buchhalter, A.R. and Stitzer, M.L. (2005) Pharmacotherapy for nicotine dependence, CA Cancer J Clin55: 281-299.
31.
Holm, K.J. and Spencer, C.M. (2000) Bupropion: a review of its use in the management of smoking cessation, Drugs59: 1007-1024.
32.
Holmes, S., Zwar, N., Jimenez-Ruiz, C.S., Ryan, P.J., Browning, D., Bergmann, L. et al. (2004) Bupropion as an aid to smoking cessation: a review of real-life effectiveness, Int J Clin Pract58: 285-291.
33.
Hughes, J., Stead, L. and Lancaster, T. (2007) Antidepressants for smoking cessation, Cochrane Database Syst Rev CD000031.
34.
Hukkanen, J., Jacob, P.III and Benowitz, N.L. (2005) Metabolism and disposition kinetics of nicotine , Pharmacol Rev57: 79-115.
Jorenby, D.E., Hays, J.T., Rigotti, N.A., Azoulay, S., Watsky, E.J., Williams, K.E. et al. (2006) Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial, JAMA296: 56-63.
37.
Lancaster, T. and Stead, L.F. (2000) Mecamylamine (a nicotine antagonist) for smoking cessation, Cochrane Database Syst Rev CD001009.
38.
Malin, D.H., Alvarado, C.L., Woodhouse, K.S., Karp, H., Urdiales, E., Lay, D. et al. (2002) Passive immunization against nicotine attenuates nicotine discrimination, Life Sci70: 2793-2798.
39.
Malin, D.H., Lake, J.R., Lin, A., Saldana, M., Balch, L., Irvin, M.L. et al. (2001) Passive immunization against nicotine prevents nicotine alleviation of nicotine abstinence syndrome, Pharmacol Biochem Behav68: 87-92.
40.
Maurer, P., Jennings, G.T., Willers, J., Rohner, F., Lindman, Y., Roubicek, K. et al. (2005) A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity, Eur J Immunol35: 2031-2040.
41.
McRobbie, H. and Hajek, P. (2004) Effect of glucose on tobacco withdrawal symptoms in recent quitters using bupropion or nicotine replacement, Hum Psychopharmacol19: 57-61.
42.
Mihalak, K.B., Carroll, F.I. and Luetje, C.W. (2006) Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors, Mol Pharmacol70: 801-805.
43.
Murphy, M.F., Hey, K., Johnstone, E., Munafo, M., Walton, R., Willis, B. et al. (2002) Bromocriptine use is associated with decreased smoking rates, Addict Biol7: 325-328.
44.
Olsen, K.R., Bilde, L., Juhl, H.H., Kjaer, N.T., Mosbech, H., Evald, T. et al. (2006) Cost-effectiveness of the Danish smoking cessation interventions: subgroup analysis based on the Danish Smoking Cessation Database, Eur J Health Econ7: 255-264.
45.
Paluck, E.C., McCormack, J.P., Ensom, M.H., Levine, M., Soon, J.A. and Fielding, D.W. (2006) Outcomes of bupropion therapy for smoking cessation during routine clinical use, Ann Pharmacother40: 185-190.
46.
Paoletti, P., Fornai, E., Maggiorelli, F., Puntoni, R., Viegi, G., Carrozzi, L. et al. (1996) Importance of baseline cotinine plasma values in smoking cessation: results from a double-blind study with nicotine patch , Eur Respir J9: 643-651.
47.
Pentel, P. and Malin, D. (2002) A vaccine for nicotine dependence: targeting the drug rather than the brain, Respiration69: 193-197.
48.
Perkins, K.A. (2002) Chronic tolerance to nicotine in humans and its relationship to tobacco dependence, Nicotine Tob Res4: 405-422.
49.
Pierce, J.P. and Gilpin, E.A. (2002) Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation, JAMA288: 1260-1264.
50.
Pomerleau, O.F. (1992) Nicotine and the central nervous system: biobehavioral effects of cigarette smoking, Am J Med93: 2S-7S.
51.
Prochazka, A.V., Kick, S., Steinbrunn, C., Miyoshi, T. and Fryer, G.E. (2004) A randomized trial of nortriptyline combined with transdermal nicotine for smoking cessation, Arch Intern Med164: 2229-2233.
52.
Schnoll, R.A., Patterson, F. and Lerman, C. (2007) Treating tobacco dependence in women, J Womens Health (Larchmt)16: 1211-1218.
53.
Sellers, E.M., Kaplan, H.L. and Tyndale, R.F. (2000) Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking, Clin Pharmacol Ther68: 35-43.
54.
Shiffman, S., West, R. and Gilbert, D. (2004) Recommendation for the assessment of tobacco craving and withdrawal in smoking cessation trials, Nicotine Tob Res6: 599-614.
55.
Siu, E.C. and Tyndale, R.F. (2007) Non-nicotinic therapies for smoking cessation, Annu Rev Pharmacol Toxicol47: 541-564.
56.
Song, F., Raftery, J., Aveyard, P., Hyde, C., Barton, P. and Woolacott, N. (2002) Cost-effectiveness of pharmacological interventions for smoking cessation: a literature review and a decision analytic analysis , Med Decis Making22(Suppl. 5): S26-S37.
57.
Stahl, S.M., Pradko, J.F., Haight, B.R., Modell, J.G., Rockett, C.B. and Learned-Coughlin, S. (2004) A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor, Prim Care Companion J Clin Psychiatry6: 159-166.
58.
Stead, L., Perera, R., Bullen, C., Mant, D. and Lancaster, T. (2008) Nicotine replacement therapy for smoking cessation , Cochrane Database Syst Rev CD000146.
59.
Tashkin, D., Kanner, R., Bailey, W., Buist, S., Anderson, P., Nides, M. et al. (2001) Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial, Lancet357: 1571-1575.
60.
Tønnesen, P., Carrozzi, L., Fagerstrøm, K.O., Gratziou, C., Jimenez-Ruiz, C., Nardini, S. et al. (2007) Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy, Eur Respir J29: 390-417.
61.
Tønnesen, P., Mikkelsen, K. and Bremann, L. (2006) Nurse-conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support, Chest130: 334-342.
62.
Tønnesen, P., Paoletti, P., Gustavsson, G., Russell, M.A., Saracci, R., Gulsvik, A. et al. (1999) Higher dosage nicotine patches increase one-year smoking cessation rates: results from theEuropean CEASE trial. Collaborative European Anti-Smoking Evaluation. European Respiratory Society, Eur Respir J13: 238-246.
63.
Tonstad, S., Tønnesen, P., Hajek, P., Williams, K.E., Billing, C.B. and Reeves, K.R. (2006) Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial, JAMA296: 64-71.
64.
Wagena, E.J., de Vos, A., Horwith, G. and van Schayck, C.P. (2008) The immunogenicity and safety of a nicotine vaccine in smokers and nonsmokers: Results of a randomized, placebo-controlled phase 1/2 trial, Nicotine Tob Res10: 213-218.
65.
Wang, D., Connock, M., Barton, P., Fry-Smith, A., Aveyard, P. and Moore, D. (2008) 'Cut down to quit' with nicotine replacement therapies in smoking cessation: a systematic review of effectiveness and economic analysis , Health Technol Assess12: 1-156.
66.
Warner, K.E. (1997) Effectiveness of smoking cessation therapies. Interpretation of the evidence-and implications for coverage, Pharmacoeconomics11: 538-549.
67.
West, R., Courts, S., Beharry, S., May, S. and Hajek, P. (1999) Acute effect of glucose tablets on desire to smoke , Psychopharmacology (Berl)147: 319-321.
68.
West, R., Gilsenan, A., Coste, F., Zhou, X., Brouard, R., Nonnemaker, J. et al. (2006) The ATTEMPT cohort: a multi-national longitudinal study of predictors, patterns and consequences of smoking cessation; introduction and evaluation of internet recruitment and data collection methods, Addiction101: 1352-1361.
69.
West, R., Hajek, P., Nilsson, F., Foulds, J., May, S. and Meadows, A. (2001) Individual differences in preferences for and responses to four nicotine replacement products, Psychopharmacology (Berl)153: 225-230.
70.
West, R., McNeill, A. and Raw, M. (2000) Smoking cessation guidelines for health professionals: an update, Thorax55: 987-999.
71.
West, R. and Willis, N. (1998) Double-blind placebo controlled trial of dextrose tablets and nicotine patch in smoking cessation, Psychopharmacology (Berl)136: 201-204.
72.
West, R. and Zhou, X. (2007) Is nicotine replacement therapy for smoking cessation effective in the 'real world'? Findings from a prospective multinational cohort study, Thorax62: 998-1002.
73.
Westman, E.C., Tomlin, K.F., Perkins, C.E. and Rose, J.E. (2001) Oral nicotine solution for smoking cessation: a pilot tolerability study, Nicotine Tob Res3: 391-396.
74.
Who Report on the Global Tobacco Epidemic ( 2008) The MPOWER Package. Geneva, World Health Organization, 2008. www.who.int/tobacco/mpoewer/mpower_report
75.
World Health Organization (1992) edn, International Classification of Diseases., 10th edition. 10thGenevaWorld Health Organization .
76.
Zellweger, J.P., Boelcskei, P.L., Carrozzi, L., Sepper, R., Sweet, R. and Hider, A.Z. (2005) Bupropion SR vs placebo for smoking cessation in health care professionals, Am J Health Behav29: 240-249.
77.
Zhang, W., Kilicarslan, T., Tyndale, R.F. and Sellers, E.M. (2001) Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro, Drug Metab Dispos29: 897-902.
